Tarsus Pharmaceuticals Inc (TARS) ニュース

Form 8-K - Current report

Form 8-K - Current report

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients...

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission...

Form 8-K - Current report